Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAIR: Alirocumab plus rosuvastatin for thin-cap fibroatheroma stabilization assessed by OCT
jRCT1051180063Completed
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial in coronary arteriosclerosis, myocardial infarction (MI), unstable angina and 1 more comparing Alirocumab + rosuvastatin with Standard-of-care lipid lowering (2 arms). Primary endpoint: Change in minimum fibrous-cap thickness. Started Sep 2017; status: completed.
02
Drugs
alirocumab
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)unstable anginaThin-cap fibroatheroma (TCFA)
Beyond the preview
Go deeper on jRCT1051180063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051180063.